BCYP

SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

Retrieved on: 
Monday, October 25, 2021
Science, LLP, Research, Immunotherapy, Technology, Lazard, Entrepreneurship, Cancer, Delta, TC, Ladenburg Thalmann, NIH, Twitter, Organ transplantation, SPAC, NASDAQ, FDA, Government, Infection, Genetic engineering, Stradling Yocca Carlson & Rauth, Nasdaq, Intention, Board, COVID-19, BCYP, M&A, Executive, Acquisition, GLOBE, SAB, Business architecture, Director, Big Cypress National Preserve, Fine chemical, Vaccine, Pharmaceutical industry

SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of its business combination with Big Cypress Acquisition Corp. (Nasdaq: BCYP) (“Big Cypress”), a publicly-traded special purpose acquisition company (SPAC) focused on innovative biopharmaceutical firms. The common stock and warrants of the resulting combined company, SAB Biotherapeutics Inc. will commence trading on the Nasdaq Global Market (the “NASDAQ”) under the ticker symbol “SABS” and “SABSW”, respectively, on October 25, 2021.

Key Points: 
  • The common stock and warrants of the resulting combined company, SAB Biotherapeutics Inc. will commence trading on the Nasdaq Global Market (the NASDAQ) under the ticker symbol SABS and SABSW, respectively, on October 25, 2021.
  • The SAB team is committed to progressing our science and expanding the reach of our unique DiversitAb platform, now as a public company.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.
  • SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

Retrieved on: 
Thursday, October 21, 2021
Registration statement, Immunotherapy, Securities Act of 1933, Lists of diseases, Cancer, Industry, TC, Name, Combination company, Twitter, Security (finance), Organ transplantation, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, NASDAQ, Big Cypress National Preserve, Infection, Antibody, SEC, Probability, Government, Communication, Review, Genetic engineering, Forward-looking statement, CEO, COVID-19, Growth, BCYP, Special, Prospectus, Acquisition, Therapy, Proxy, SAB, Business, Nasdaq, Doctor of Philosophy, Business architecture, Cypress, Register, Sale, Management

Any outstanding units of Big Cypress, consisting of shares of Big Cypress common stock and warrants to purchase Big Cypress common stock, will automatically separate into the equivalent number of common stock and warrants of the Combined Company upon the consummation of the Business Combination.

Key Points: 
  • Any outstanding units of Big Cypress, consisting of shares of Big Cypress common stock and warrants to purchase Big Cypress common stock, will automatically separate into the equivalent number of common stock and warrants of the Combined Company upon the consummation of the Business Combination.
  • On October 20, 2021, the stockholders of Big Cypress voted in favor of a proposal to approve the Business Combination at the special meeting of stockholders.
  • Investors and security holders of Big Cypress are advised to read the proxy statement/prospectus in connection with Big Cypress' solicitation of proxies for its special meeting of stockholders to be held to approve the proposed business combination (and related matters) because the proxy statement/prospectus contains important information about the proposed business combination and the parties to the proposed business combination.
  • Big Cypress, SAB and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Big Cypress' stockholders in connection with the proposed business combination.

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Infection, Securities Act of 1933, Probability, Endocrinology, SAB, College, Pediatric endocrinology, Proxy, Johns Hopkins School of Medicine, Sale, Organ transplantation, NASDAQ, Private Securities Litigation Reform Act, Cancer, Webcast, Registration statement, MD, Bloomberg, TC, BCYP, University of Florida, Johns Hopkins Bloomberg School of Public Health, Immunotherapy, Twitter, University, Communication, Immunology, Register, COVID-19, Big Cypress National Preserve, Public health, Genetic engineering, Forward-looking statement, Prospectus, Doctor of Philosophy, Alfred, Government, Name, SEC, Vaccine, Public relations

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m.

Key Points: 
  • SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m.
  • A replay of the webcast will be available on the SAB website following the event.
  • On June 22, 2021, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP).
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, BCYP, Form, CDC, Immunotherapy, Government, SAB, Private Securities Litigation Reform Act, Forward-looking statement, A type, Prospectus, Genetic engineering, Doctor of Philosophy, Patient, Proxy, Viral load, Register, Securities Act of 1933, Risk, Influenza, Big Cypress National Preserve, Use-centered design, Probability, Safety, Infection, Vaccine, NASDAQ, Communication, TC, COVID-19, Twitter, Name, Population, Real-time, Registration statement, SEC, Organ transplantation, Sale, Cancer, SAB-176, Seasonal Influenza, SAB Biotherapeutics, Inc., SAB-176, SEASONAL INFLUENZA, SAB BIOTHERAPEUTICS, INC.

SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza.

Key Points: 
  • SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza.
  • The Phase 2a clinical trial is a randomized, double-blind, placebo-controlled study that is evaluating the safety and treatment efficacy of SAB-176 in 60 healthy adults challenged with a pandemic influenza virus strain (pH1N1).
  • SAB-176 is also currently being evaluated in a Phase 1 ascending dose, double-blind, randomized, placebo-controlled safety trial in healthy volunteers, which has also completed enrollment.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.

SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

Retrieved on: 
Wednesday, September 8, 2021
Biotechnology, Pharmaceutical, Health, Other Health

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.

Key Points: 
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.
  • SABs versatile DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases.
  • SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.
  • Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of RIVE, IACB, BCYP, and RFL Mergers

Retrieved on: 
Wednesday, August 18, 2021
RFL, Fraud, GLOBE, NYSE, BCYP, NASDAQ, Property management, Online gambling

Under the terms of the agreement, Riverviews shareholders will receive 0.4833 shares of Mid Penn common stock per share.

Key Points: 
  • Under the terms of the agreement, Riverviews shareholders will receive 0.4833 shares of Mid Penn common stock per share.
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-riverview-financial-corporation .
  • Rafael Holdings, Inc. (NYSE: RFL ) regarding possible breaches of fiduciary duties and other violations of law related to Rafaels agreement to merge with Rafael Pharmaceuticals, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-rafael-holdings-inc .
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .